Controlled clinical trial of cannabidiol in Huntington's disease

@article{Consroe1991ControlledCT,
  title={Controlled clinical trial of cannabidiol in Huntington's disease},
  author={Paul F. Consroe and Joan Laguna and James Allender and Stuart R. Snider and Lawrence Z. Stern and Reuven Sandyk and Kurt Kennedy and Karl H. Schram},
  journal={Pharmacology Biochemistry and Behavior},
  year={1991},
  volume={40},
  pages={701-708}
}
Based on encouraging preliminary findings, cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, was evaluated for symptomatic efficacy and safety in 15 neuroleptic-free patients with Huntington's Disease (HD). The effects of oral CBD (10 mg/kg/day for 6 weeks) and placebo (sesame oil for 6 weeks) were ascertained weekly under a double-blind, randomized cross-over design. A comparison of the effects of CBD and placebo on chorea severity and other therapeutic outcome variables, and… Expand
Cannabidiol monotherapy for treatment-resistant schizophrenia
TLDR
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days. Expand
A systematic review of cannabidiol dosing in clinical populations
TLDR
CBD was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of CBD on reducing seizure frequency or severity, and it is highlighted that CBD has a potential wide range of activity in several pathologies. Expand
Cannabidiol was ineffective for manic episode of bipolar affective disorder
TLDR
The preliminary data suggest that CBD may not be effective for the manic episode of BAD, and the efficacy, tolerability and side effects were assessed. Expand
Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
TLDR
A selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric disorders, found CBD to be safe, well-tolerated and efficacious in mitigating the symptoms associated with several types of seizure disorders and childhood epilepsies. Expand
Cannabidiol in Humans—The Quest for Therapeutic Targets
TLDR
Preliminary clinical trials suggest that high-dose oral CBD may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation. Expand
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
TLDR
It is suggested that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas and the effects of this compound on human pathological anxiety and its underlying brain mechanisms. Expand
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.
TLDR
In the first ever controlled trial of a CBM in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following Sativex treatment. Expand
Cannabidiol (CBD) use in psychiatric disorders: A systematic.
TLDR
There is currently limited evidence regarding the safety and efficacy of CBD for the treatment of psychiatric disorders, however, available trials reported potential therapeutic effects for specific psychopathological conditions, such as substance use disorders, chronic psychosis, and anxiety. Expand
Cannabinoids for the Treatment of Movement Disorders
TLDR
There is growing evidence of a “cannabinoid entourage effect” in which a combination of cannabinoids derived from the plant are more effective than any single cannabinoid for a number of conditions. Expand
The development of Cannabidiol as a psychiatric therapeutic: a review of its antipsychotic efficacy and possible underlying pharmacodynamic mechanisms
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary constituents of cannabis, alongside delta-9-tetrahydrocannabinol (?9-THC/THC). In the last 30 years, CBD hasExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
TLDR
Four of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition, while CBD was ineffective in 1 patient. Expand
Open label evaluation of cannabidiol in dystonic movement disorders.
TLDR
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study and appears to have antidystonic and Parkinsonism-aggravating effects in humans. Expand
Pharmacokinetics of cannabidiol in dogs.
TLDR
The results of this study show that CBD is barely absorbed after oral administration to dogs, and this low bioavailability may be due to a first pass effect. Expand
Serum haloperidol concentration and choreiform movements in Huntington's disease
TLDR
The relationship between serum haloperidol concentration and improvement in abnormal movements was investigated in 20 adult Huntington's disease (HD) patients and results from the GC/MS assay were used for examining relationships with dose and clinical response because of insensitivity of RR assay. Expand
Metabolic and psychophysiologic studies of cannabidiol‐hexobarbital interaction
TLDR
Cannabidiol (CBD), 600 mg/day orally for 5 to 12 days, inhibited hexobarbital metabolism in ten subjects, which increased fatigue and tremor, impaired eye‐tracking performance, and altered the electroencephalogram. Expand
Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration.
TLDR
The disposition of deuterium-labelled cannabidiol, 2H2-CBD, was studied in five young men who were marihuana smokers and a four-fold difference in the availability of the compound was noted for the five subjects. Expand
Huntington disease
TLDR
The Commission for the Control of Huntington Disease and Its Consequences, established by the Ninety-Fourth United States Congress, recently completed an appraisal of clinical care of the patient and family with Huntington disease. Expand
Assessment of extrapyramidal disorders.
In the last twenty years the accurate evaluation of extrapyramidal disorders has become essential to assess the efficacy of an increasing number of potentially useful drugs. Not surprisingly, sinceExpand
Drug Treatment of Huntington's Chorea
TLDR
In Huntington's chorea the main features requiring treatment are dementia and a psychosis, in addition to the chronic choreic movements from which the title derives, and the advent of the phenothiazine derivatives has for the first time brought some measure of relief to their patients. Expand
Observations on the use of methysergide in Huntington's chorea
TLDR
The relative significance of the serotonergic mechanisms in the pathophysiology of chorea was investigated by observing the effect of methysergide on patients with Huntington’s chorea. Expand
...
1
2
3
...